Regulatory Amgen’s BiTE for lung cancer backed for EU approval PharmaphorumAmgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 30, 2026) Pharmaphorum Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Trustworthy AI in clinical oversightNext: The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
